John Kuelper
Co-Founder & CEO; Managing Director @ Ascension Ventures
Saint Louis, United States
John Kuelper is a Series D investor at Ascension Ventures in Saint Louis focused on Health Care and Medical. John Kuelper joined Ascension Ventures in 2014 as a Kauffman Fellow. John is Founder and President of Qualia Holdings LLC, a platform for systems biology and therapeutic ventures. He has advised or worked for several investment firms (Adams Street Partners, Sterling Partners, Abundant Venture Partners), medical technology companies (Stereotaxis,Orpheden Therapeutics), and non-profits (The Kresge Foundation, the Blue Cross and Blue Shield Association). John began his career as a medical researcher studying computational neuroscience and medical robotics and has over fifteen years of experience as a commercial software developer. John earned JD and MBA degrees from the Northwestern University Pritzker School of Law and Kellogg School of Management where he graduated with honors and was elected Beta Gamma Sigma (top 10% of class). He earned a BA in cognitive neuroscience from Washington University in St. Louis, graduating magna cum laude. In 2014 he was elected to the Kauffman Fellows Society. In his spare time, John enjoys hiking and camping with his two dogs and listening to live music.
- Total investments:
- 15
- Last investment:
- Lead investor:
- 53%
Last updated:
For AI agents: llms.txt
Industries John Kuelper invests in
Stages John Kuelper invests in
Countries John Kuelper invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 7 (47%)
- Medical 3 (20%)
- Software 2 (13%)
- Precision Medicine 2 (13%)
- Information Technology 2 (13%)
Stage
- Series D 4 (27%)
- Series A 3 (20%)
- Series C 3 (20%)
- Series B 1 (7%)
- Series E 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Cofactor Genomics is a company focused on predictive immune modeling. They aim to advance precision medicine by overcoming existing barriers. Cofactor facilitates the shift from single-analyte biomarkers to more comprehensive multidimensional biomarkers using health expression models. Their capabilities include molecular, informatic, and databasetools, with one of the first CAP-certified clinical RNA sequencing laboratories. This certification helps their partners conduct clinical trials more efficiently and cost-effectively. Their expertise in molecular biology, informatics, and database management enables them to provide high-quality services to the healthcare and pharmaceutical sectors, contributing to medical research and improving patient outcomes. | Venture - Series Unknown / Dec 15, 2025 | ||
| NextSense unlocks brain health with real-world data insights and practical, scientific wisdom for daily living. It aims to catalyze brain health in science and culture. The company was founded in 2020 and is headquartered in Mountain View, California. | $16.3M / Series A / Nov 11, 2025 | ||
| Cala Health is a bioelectronic medicine company transforming the standard of care for chronic disease. The company's wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation. The first indication for Cala Health's wearable therapy is an essential tremor, adisease experienced by more than seven million people and characterized by severe hand tremors. New therapies are under development in neurology, cardiology, and psychiatry. The company is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology. | $50M / Series C / Dec 09, 2024 | ||
| Elation Health is the most trusted technology platform for independent primary care. Since 2010, the company has delivered clinical-first solutions - built on an award-winning collaborative electronic health record - that help practices start, grow, communicate, and succeed in delivering the highest-quality personalized primary care to patients.Elation Health is empowering primary care clinicians to uphold the craft of medicine while thriving in an evolving healthcare landscape. Today, Elation Health serves 14,000 clinicians caring for 7 million Americans. | $50M / Series D / Jul 26, 2022 | ||
| Cala Health is a bioelectronic medicine company transforming the standard of care for chronic disease. The company's wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation. The first indication for Cala Health's wearable therapy is an essential tremor, adisease experienced by more than seven million people and characterized by severe hand tremors. New therapies are under development in neurology, cardiology, and psychiatry. The company is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology. | $77M / Series D / Nov 16, 2021 | ||
| AristaMD is a healthcare company that features a software platform that helps hospitals and practitioners on improving patient outcomes. It also offers a solution that enables primary care providers to ask questions about patients that they would otherwise refer out and transmit patient clinical notes, history, lab results and images to collaborateon care plans with a panel of on-call, board-certified specialists, all within a matter of hours.The company was founded in 2013 and headquartered in La Jolla, California. | $6M / Series B / Jul 14, 2020 | ||
| To achieve more precise care for every patient, we need to transform real-world evidence into insights that can directly impact care. At Syapse, that is real-world care. It’s found in the way we empower healthcare organizations to work together in active, transparent partnerships, delivering complete patient insights to answer the questions thatmatter and then purposefully applying it at where patients receive care – driving real impact for cancer patients and beyond. | $30M / Series F / May 28, 2020 | ||
| Reputation.com delivers an Online Reputation Management (ORM) platform for large enterprises with hundreds or thousands of locations. The platform provides a 360-degree view of online reputation and allows clients to manage online reviews, social media, business listings, and customer surveys. Its advanced analytics and reporting capabilitiesdeliver valuable operational insights that help clients be more efficient, deliver better service and drive traffic, visits, and revenue.Businesses can also gain valuable insights at the local level that will give it the information needed to make operational changes to maximize customer retention and revenue.Reputation.com was founded on 2006 and is headquartered in Redwood City, California. | $30M / Aug 20, 2019 | ||
| Reputation.com delivers an Online Reputation Management (ORM) platform for large enterprises with hundreds or thousands of locations. The platform provides a 360-degree view of online reputation and allows clients to manage online reviews, social media, business listings, and customer surveys. Its advanced analytics and reporting capabilitiesdeliver valuable operational insights that help clients be more efficient, deliver better service and drive traffic, visits, and revenue.Businesses can also gain valuable insights at the local level that will give it the information needed to make operational changes to maximize customer retention and revenue.Reputation.com was founded on 2006 and is headquartered in Redwood City, California. | $34.9M / Series C / Aug 20, 2019 | ||
| To achieve more precise care for every patient, we need to transform real-world evidence into insights that can directly impact care. At Syapse, that is real-world care. It’s found in the way we empower healthcare organizations to work together in active, transparent partnerships, delivering complete patient insights to answer the questions thatmatter and then purposefully applying it at where patients receive care – driving real impact for cancer patients and beyond. | $20M / Series E / Jan 28, 2019 | ||
| See all 15 investments → | |||
Co-Investors
About Ascension Ventures
AHV was established in 2001 by Ascension Health with a commitment of $125 million to invest in expansion- to late-stage healthcare companies. Ascension Health is the nation's largest Catholic and largest nonprofit health system serving patients through a network of hospitals and health facilities in 20 states and the District of Columbia. AHVoffers its limited partners the ability to earn venture-level financial returns while providing early insight to future healthcare developments.
Ascension Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Brendan Salvino
Senior Associate
|
|||
Brian Belsky
Principal
|
|||
Jamie Wehrung
Chief Administrative Officer
|
|||
|
John Kuelper
Co-Founder & CEO; Managing Director
|
|||
Matt Hermann
Senior Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does John Kuelper invest in?
John Kuelper invests primarily in Health Care, Medical and Software startups, most often at Series D and Series A stage. Most of the 15 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact John Kuelper?
Public channels for John Kuelper include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did John Kuelper last invest?
The most recent investment recorded for John Kuelper closed in Dec 2025. Shizune tracks 15 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
